Explore more publications!

Eureka State News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Eureka State News.

Press releases published on December 7, 2025

Naval Aviator Turned NPS Doctoral Student Earns National Recognition for Applied Quantum Research
PROPSTORE ACHIEVES $10.2 MILLION IN DAY ONE RESULTS AS LONDON ENTERTAINMENT MEMORABILIA AUCTION OPENS STRONGLY
'The Breaking of Time' by J.J. Hebert Hits No. 1 Amazon Best Seller & Top New Release
COGNNA announces a $9.2M Series A led by Impact46 with participation from BNVTCapital, VisionVentures, and TaliVentures.
Disruptive Futures Institute Names Metaruptions 2026 Word of the Year & Launches Roger Spitz’s Visionary Keynote Series
Gurjit Singh Chadha releases transformative New Book: Unraveling Your True Self – Discovering the Essence of 'Who Am I?'
Zensa Skin Care Expands Its Presence in Aesthetic Clinics Nationwide
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions